Metformin use may be associated with decreased risk of prostate cancer
the ONA take:
According to a new study published in the journal European Urology, researchers have found that metformin use was associated with a decreased risk of prostate cancer diagnosis while other oral antihyperglycemics had no decreased risk.
For the nested case-control study, researchers identified 12,226 cases of prostate cancer among men residing in Northern Denmark between 1989 and 2011 from the Danish Cancer Registry and the Aarhus University Prescription Database.
They found that compared with never-users of metformin, metformin users had a decreased risk of prostate cancer diagnosis (adjusted OR = 0.84, 95% CI: 0.74 - 0.96). In addition, diabetics on no antihyperglycemics (adjusted OR = 0.98, 95% CI: 0.89 - 1.09) or on oral antihyperglycemics other than metformin (adjusted OR = 0.98, 95% CI: 0.86 - 1.10) did not have a decreased risk of prostate cancer. Insulin users also had a decreased risk of prostate cancer (adjusted OR = 0.77, 95% CI: 0.64 - 0.93).
Furthermore, among patients who had prostate-specific antigen (PSA) testing prior to 1 year before being indexed, metformin users had a decreased risk of prostate cancer versus nonusers (adjusted OR = 0.66, 95% CI: 0.51 - 0.86). In the same PSA-tested group, diabetics on no medication, other oral antihyperglycemics, or insulin did not have a significant reduced risk of the disease.
Metformin use associated with decreased risk of prostate cancer diagnosis.
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Shifts in Cancer Burden for People With HIV Projected
- Tissue Biobank Procurement Consent Should Include Discussion of Confidentiality Risks
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|